Consent documents, reproductive issues, and the inclusion of women in clinical trials

Purpose. To describe language used in consent documents at one academic med ical center to inform women participating in studies of potential reproduct ive and fetal risks. Method. The authors reviewed consent document language describing reproduct ive and fetal risks in 114 approved protocols. Protocols were identified as being of high, low, or unknown risk based upon FDA drug-risk and radiation -risk categories. Results. Although most consent documents advised women against participatin g for one or more pregnancy-related reasons, specific information about rep roductive or fetal risks was included in fewer consent documents: 8 (73%) o f the high risk studies, 12 (40%) of the low-to-moderate-risk studies, and 29 (40%) of the unknown-risk studies. Conclusions. Investigators often omit fetal risk information from consent d ocuments. Full disclosure of reproductive and fetal risks in consent docume nts and discussions can be taught and modeled during the research training period. The authors present a template with language that can be used in co nsent documents and recommend ongoing discussion of reproductive and fetal risks with women subjects throughout the study period.